Figures & data
Figure 1 Wnt signaling pathways and the biology of sclerostin.
![Figure 1 Wnt signaling pathways and the biology of sclerostin.](/cms/asset/38bdbbb8-e820-4654-889f-72fbaa01cba2/djwh_a_73244_f0001_c.jpg)
Figure 2 Clinical effects of sclerosteosis and van Buchem disease.
![Figure 2 Clinical effects of sclerosteosis and van Buchem disease.](/cms/asset/0996fda4-239e-43fd-9e3b-c260e159a052/djwh_a_73244_f0002_c.jpg)
Figure 3 The effect of sclerostin inhibition on Wnt signaling.
Abbreviation: MAb, monoclonal antibody.
![Figure 3 The effect of sclerostin inhibition on Wnt signaling.](/cms/asset/f37d1bef-416f-45ca-92ef-aac80440dc0e/djwh_a_73244_f0003_c.jpg)
Table 1 Summary of Phase I and II studies of romosozumab
Table 2 Summary of Phase III studies of romosozumab in osteoporosisTable Footnote*